Catalog No.
Product Name
Application
Product Information
Citations
-
Antibacterial Agent
Cloxacillin is an orally active antibacterial agent and β-lactamase inhibitor, exhibiting an IC50 of 0.04 µM. It effectively suppresses the inflammatory response induced by Staphylococcus aureus by inhibiting the activation of mitogen-activated protein kinases (MAPKs), nuclear factor kappa B (NF-κB), and proteins associated with the NLRP3 inflammasome. This compound is useful for research applications focused on bacterial infections and inflammatory processes. -
Sesquiterpene
Terrecyclic Acid is a sesquiterpene derived from the fungal species Aspergillus terreus. This compound exhibits notable antibiotic and anticancer properties, demonstrating activity against Staphylococcus aureus, Bacillus subtilis, and Micromonospora roseus with minimum inhibitory concentrations of 25, 50, and 25 μg/mL, respectively. Additionally, terrecyclic acid induces a heat shock response, elevates reactive oxygen species (ROS) levels, and suppresses NF-κB activity and cellular proliferation in 3T3-Y9-B12 cells. In vivo studies reveal that terrecyclic acid effectively reduces ascitic fluid tumor cell counts in a mouse model of P388 murine leukemia at concentrations of 0.1, 1, and 10 mg/mL. -
TPA Negative Control
4α-TPA is an inactive analog of TPA, serving as a negative control in TPA-mediated experiments. This reagent is critical for distinguishing specific TPA-activated events from non-specific responses in biological assays. It aids researchers in validating experimental outcomes related to TPA signaling pathways and discerning the effects of TPA on various cellular processes. -
PKC Inhibitor
PKC-IN-4 is a selective inhibitor of atypical protein kinase C (aPKC) with an IC50 of 0.52 µM. This compound effectively inhibits TNF-α-induced NF-κB signaling in vitro, making it a valuable tool for studies involving inflammatory responses. Additionally, PKC-IN-4 has been shown to block VEGF- and TNF-α-induced permeability across the retinal vasculature, highlighting its potential in retinal disease research and vascular permeability exploration. -
Survivin Inhibitor
Isonanangenine B is a selective inhibitor of survivin, exhibiting an IC50 of 1.6 µM. It effectively obstructs the interaction of critical transcription factors, including Stat3 and NF-κB, with the survivin promoter. This compound holds potential for advancing cancer research, particularly in elucidating the mechanisms of survivin modulation in tumorigenesis. -
Doxorubicin Glycoside Ligand
Doxorubicinone is the aglycone form of the anthracycline antibiotic Doxorubicin, functioning primarily as a Doxorubicin glycoside ligand. It exhibits notable anti-inflammatory activity by downregulating the expression of pro-inflammatory cytokines, including TNF and IL-12, through modulation of the NF-κB signaling pathway. Doxorubicinone is particularly useful in research related to sepsis and other inflammatory conditions, providing insights into cytokine regulation without inducing DNA damage. -
TNF-α/NF-κB Inhibitor
TNF-α-IN-28 is a selective inhibitor of TNF-α and NF-κB, demonstrating significant anti-inflammatory activity. This compound effectively inhibits the expression of both TNF-α and NF-κB by targeting the TNF-α dimer. TNF-α-IN-28 is intended for use in research applications focused on inflammation, immune response modulation, and related signaling pathways. -
CDK8/19 Inhibitor
Senexin A hydrochloride is a selective inhibitor of cyclin-dependent kinases 8 and 19 (CDK8 and CDK19), with an IC50 of 280 nM for CDK8. It specifically targets and inhibits p21-induced transcription, while sparing other biological functions of p21. In addition, Senexin A hydrochloride effectively suppresses CMV-GFP induction and the p21 stimulatory activity of NF-κB-dependent promoters, making it a valuable tool for studying transcriptional regulation and cell signaling pathways. -
CDK8 Inhibitor
CDK8-IN-15 is a selective inhibitor of cyclin-dependent kinase 8 (CDK8), exhibiting a potent IC50 of 57 nM. This compound enhances the thermal stability of CDK8 while effectively inhibiting NF-κB signaling pathways. CDK8-IN-15 demonstrates promising biological activity in an in vitro psoriasis model induced by TNF-α, alleviating inflammation and promoting the expression of anti-inflammatory markers such as Foxp3 and IL-10. This makes it a valuable tool for research into psoriasis and related inflammatory disorders. -
CTH/H2S/NF-κB/EMT Inhibitor
TKL002 is a selective inhibitor targeting the CTH/H2S/NF-κB/EMT signaling pathway, proven to penetrate the blood-brain barrier. It effectively induces G2/M phase cell cycle arrest and apoptosis in glioblastoma cells, simultaneously inhibiting their migration and invasion. This compound upregulates E-cadherin while downregulating N-cadherin and vimentin, making it a valuable tool for investigative studies in glioblastoma research. -
Survivin Inhibitor
MX107 is a selective survivin inhibitor known for its potent efficacy in suppressing the proliferation of triple-negative breast cancer (TNBC) cells. By inducing the degradation of survivin and inhibitor-of-apoptosis proteins (IAPs), MX107 effectively inhibits nuclear factor κB (NF-κB) activation in response to DNA damage. This compound enhances the tumoricidal effects of genotoxic treatments when used in conjunction with chemotherapeutic agents, making it a valuable tool in cancer research and therapy development. -
RIPK2 Inhibitor
CSLP43 is a selective inhibitor of RIPK2, demonstrating an IC50 of 19.9 nM against human RIPK2. By binding to the ATP-binding pocket of RIPK2, CSLP43 disrupts its interaction with the BIR2 domain of XIAP and cIAP1, effectively inhibiting RIPK2 ubiquitination and regulating NOD1- and NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation. This compound is particularly relevant for research investigating Crohn's disease, Blau syndrome, early-onset sarcoidosis, and early-onset inflammatory bowel disease, due to its selectivity for the NOD1/NOD2 signaling pathway without affecting RIPK1 or RIPK3 activity. -
NF-κB Inhibitor/p53 Activator
CBLC100 is an NF-κB inhibitor and a p53 activator that exhibits potent anticancer properties. By targeting FACT, CBLC100 induces cytotoxicity through both p53-dependent apoptotic and non-apoptotic pathways. This compound is particularly relevant for research applications centered on cancers, including fibrosarcoma, making it a valuable tool for studying tumorigenesis and therapeutic responses. -
p53-MDM2 Inhibitor
p53-MDM2-IN-2 is an orally active inhibitor targeting the p53-MDM2 interaction, exhibiting a Ki value of 0.25 μM. This compound demonstrates antitumor activity through the inhibition of the NF-κB signaling pathway. It is valuable in research studies focusing on cancer therapy and elucidating the molecular mechanisms of tumor suppression. -
p53-MDM2 Inhibitor
p53-MDM2-IN-3 is a potent p53-MDM2 inhibitor with a Ki value of 0.25 μM, demonstrating oral bioavailability. This compound exhibits significant antitumor activity through its inhibition of the NF-κB signaling pathway. It serves as a valuable tool for cancer research, particularly in studies focused on targeting the p53-MDM2 interaction and the subsequent effects on tumor proliferation and survival. -
AURKC-IκBα Interaction Inhibitor
AKCI is an AURKC-IκBα interaction inhibitor with an IC50 value of 24.9 μM. It effectively induces G2/M cell cycle arrest in MDA-MB-231 cells by modulating the p53/p21/CDC2/cyclin B1 signaling pathway, while also inhibiting cell migration and invasion. Additionally, AKCI reduces colony formation and tumor growth, making it a valuable tool for investigating breast cancer mechanisms. -
Herbicide/Microtubule inhibitor
Ethalfluralin is a dinitroaniline herbicide that functions as a microtubule inhibitor. By disrupting intranuclear spindle formation, Ethalfluralin effectively obstructs nuclear division and cytokinesis in parasites. This compound also enhances phosphorylation of NF-κB and P38 MAPK while inhibiting the PI3K/AKT signaling pathway, leading to impaired mitochondrial functionality, apoptosis, endoplasmic reticulum stress, autophagy, and increased reactive oxygen species (ROS) production. Ethalfluralin is particularly relevant for research applications in toxoplasmosis and related parasitic diseases. -
NLRP3 Inhibitor
NLRP3-IN-78 is a potent inhibitor of the NLRP3 inflammasome, demonstrating a 46.72% inhibition rate in GSDMD-induced pyroptosis at a concentration of 5 μM. This compound effectively binds to the NLRP3 protein, hindering GSDMD-NT oligomerization and cleavage while also suppressing upstream NF-κB signaling. NLRP3-IN-78 serves as a valuable tool for investigating anti-inflammatory mechanisms and the role of NLRP3 in various disease models. -
FIKK9.1 Inhibitor
FIKK9.1-IN-1 is a selective inhibitor of the protein kinase FIKK9.1, targeting its ATP-binding residues. This compound demonstrates significant biological activity as an antimalarial agent, exhibiting an IC50 value of 2.68 μg/mL. By disrupting the life cycle of malaria parasites, FIKK9.1-IN-1 facilitates their elimination, making it a valuable tool for research focused on malaria intervention strategies. -
Contrast Medium
Perflubron (Perfluorooctyl bromide) serves as a contrast medium for magnetic resonance imaging (MRI) and sonography. It exhibits the ability to inhibit chemokine expression and NF-κB activation, contributing to its anti-inflammatory, antiviral, and cytoprotective effects. Perflubron can be emulsified with egg phospholipids, facilitating its use in various imaging applications, and is characterized by notably rapid excretion properties, making it a valuable reagent in clinical and research settings. -
EPAC2 Inhibitor
MAY0132 is a potent and selective inhibitor of the EPAC2 pathway, exhibiting an IC50 of 0.4 μM. This compound significantly impedes the replication of human metapneumovirus (HMPV), adenovirus (AdV), and respiratory syncytial virus (RSV), while also decreasing cytokine and chemokine production induced by viral infections. Furthermore, MAY0132 inhibits NF-κB activation, underscoring its utility in research focused on antiviral mechanisms and respiratory virus pathogenesis. -
STING Activator
diABZI-4 is a potent STING activator that enhances the host immune response through immunostimulatory activity. By promoting STING oligomerization, diABZI-4 activates the TBK1-IRF3 and NF-κB signaling pathways, leading to increased production of type I/III interferons and proinflammatory cytokines. This reagent demonstrates broad-spectrum antiviral efficacy against various viruses, including influenza A, SARS-CoV-2, and herpes simplex virus. diABZI-4 is instrumental in research related to COVID-19, respiratory viral infections, and the associated immunopathological mechanisms, making it a valuable tool for studying viral pathogenesis and developing therapeutic strategies. -
Influenza Virus Inhibitor
Amizon is an orally effective antiviral agent targeting the influenza virus. It inhibits viral replication and restricts RNA synthesis, while simultaneously reducing the mRNA expression of pro-inflammatory mediators such as COX-1, COX-2, NF-κB, TGF-β1, IL-1, and IL-6. Additionally, Amizon enhances the secretion and mRNA expression of the anti-inflammatory cytokine IL-10 and exhibits antioxidant properties, inhibiting the oxidative activity of macrophages. This compound is of interest in research focused on influenza and acute respiratory viral infections. -
Parasite Inhibitor
8-Deoxygartanin, a prenylated xanthone derived from Garcinia mangostana, serves as a selective inhibitor of butyrylcholinesterase (BChE). This compound demonstrates significant antiplasmodial activity, with an IC50 value of 11.8 μM against the W2 strain of Plasmodium falciparum. Additionally, 8-Deoxygartanin inhibits NF-κB (p65) activation, displaying an IC50 of 11.3 μM, making it a valuable reagent for research in parasitic infections and inflammation pathways. -
FIKK Inhibitor
GSK2181306A is a pan-FIKK inhibitor that exhibits an EC50 value of 0.16 μM for the inhibition of parasite growth. This compound is valuable for research focused on Plasmodium infections, enabling exploration of FIKK pathways in parasitic disease mechanisms and potential therapeutic interventions. -
Stable Isotope
Estragole-d4 is a deuterated form of Estragole, primarily utilized as a stable isotope for labeling studies. As a volatile terpenoid ether, Estragole exhibits significant biological activities, including the induction of apoptosis and the inhibition of LPS-induced reactive oxygen species (ROS) production. It also activates the Nrf-2 pathway and regulates NF-κB signaling, contributing to its anti-inflammatory, antioxidant, and immunomodulatory properties. Estragole has been investigated for its potential effects on neuronal excitability and gastric ulcer amelioration, making it valuable in various research applications. -
HCV/HDAC6 Inhibitor
Nicoxamat, also known as N-Hydroxynicotinamide, functions as an inhibitor of hepatitis C virus (HCV) and selectively targets HDAC6. This compound exhibits antiviral activity against HCV, making it a useful tool in research on hepatitis C infection. Its role as an HDAC6 inhibitor further supports investigations into epigenetic regulation and potential therapeutic strategies. -
HIV-1 Latency-Reversing Agent
Ciapavir is an HIV-1 latency-reversing agent that targets cIAP1, facilitating the degradation of this inhibitor and subsequently activating the non-canonical NF-κB pathway. This compound effectively reverses latent HIV-1 reservoirs both in vitro and in vivo, while minimizing systemic T cell activation and broad cytokine release. Ciapavir is a valuable tool for research into HIV-1 infection and the mechanisms of latency reversal. -
Stable Isotope
Myristic acid-13C2 is a stable isotope-labeled variant of myristic acid, a saturated 14-carbon fatty acid commonly found in various animal and plant fats, including milk fat and coconut oil. This compound exhibits anti-inflammatory effects primarily through the NF-κB signaling pathway and demonstrates antibacterial, anti-inflammatory, and analgesic activities. Myristic acid-13C2 is valuable in metabolic studies, allowing researchers to investigate fatty acid metabolism and functionality in biochemical pathways. -
IFN-γ Promoter Enhancer
Centaurein is a flavonoid that functions as an enhancer of the IFN-γ promoter, significantly up-regulating the activity of NFAT and NF-κB enhancers. It has been shown to increase IFN-γ expression in T and NK cells, resulting in elevated serum IFN-γ levels in murine models. Additionally, Centaurein induces complete relaxation of contractions in intact rat aortic rings and demonstrates protective effects against Listeria infection in mice, making it a valuable tool for research in immunology and vascular biology. -
Proteasome Inhibitor
PR-39 is a natural proline- and arginine-rich antibacterial peptide that functions as a noncompetitive, reversible allosteric inhibitor of the proteasome. By binding to the α7 subunit of the proteasome, PR-39 effectively blocks the degradation of NF-κB inhibitor IκBα through the ubiquitin-proteasome pathway. This compound demonstrates key biological activities such as stimulating angiogenesis and inhibiting inflammatory responses, making it a valuable tool for research on myocardial infarction and inflammatory diseases. -
GPR120 Agonist
9-PAHSA is a potent endogenous agonist of the GPR120 receptor, demonstrating an EC50 of 18 μM. This compound effectively inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway, showcasing its anti-inflammatory properties. Additionally, 9-PAHSA promotes adipocyte browning, enhances glucose uptake, and diminishes lipid accumulation, while supporting mitochondrial function in steatotic hepatocytes. It also exhibits neuroprotective effects by modulating the expression of REST and BDNF in the prefrontal cortex of diabetic mice, preventing cognitive deficits and abnormal social behaviors. 9-PAHSA is valuable for research into diabetes-related cognitive impairment, obesity, and non-alcoholic fatty liver disease. -
CXCR2 Receptor Antagonist
AZ10397767 is a selective antagonist of the CXCR2 receptor, exhibiting an IC50 of 1 nM. This compound effectively reduces NF-κB transcriptional activity induced by Oxaliplatin and enhances apoptosis in androgen-independent prostate cancer (AIPC) cells. Additionally, AZ10397767 significantly diminishes neutrophil recruitment to tumors, which may inhibit tumor growth in both in vitro and in vivo models, making it a valuable tool in cancer research. -
apoE-mimetic Peptide
COG112 is an antennapedia-linked apoE-mimetic peptide that targets inflammatory pathways. It effectively attenuates nitric oxide production and inhibits the expression of CXC chemokines such as KC and MIP-2. Additionally, COG112 reduces the nuclear translocation of NF-κB and inhibits the phosphorylation of IκB-α, thereby preventing its degradation. This peptide is valuable for research applications focused on modulating inflammatory responses, particularly in the context of Citrobacter rodentium infection. -
ADRB2 Agonist
Indacaterol xinafoate is a potent β2-adrenergic receptor agonist known for its long-acting bronchodilatory effects. By inhibiting NF-κB activity in a β-arrestin2-dependent manner, it not only improves lung function but also mitigates further lung damage, making it relevant in the context of chronic obstructive pulmonary disease (COPD). This compound serves as a valuable tool for research into asthma and related respiratory disorders. -
cGAS Inhibitor
cGAS-IN-9 is an inhibitor of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) with IC50 values of 27.5 nM and 5.15 μM for human and murine cGAS, respectively. This compound demonstrates weak inhibitory activity against human soluble adenylate cyclase, with an IC50 of 26.4 μM. cGAS-IN-9 significantly reduces dsDNA-induced expression of IFNB1 and CXCL10, as well as inhibits the activation of the NF-κB pathway in human immune cells. It is a valuable tool for research on cGAS-dependent inflammatory diseases. -
ADRB2 Agonist
Indacaterol acetate is an orally active ultra-long-acting agonist of the β2 adrenergic receptor (ADRB2). It exhibits anti-inflammatory properties by inhibiting NF-κB activity in a β-arrestin2-dependent manner, thereby mitigating lung damage and enhancing lung function in chronic obstructive pulmonary disease (COPD). Additionally, Indacaterol acetate serves as a valuable reagent in cardiovascular disease research. -
Adrenergic Receptor Antagonist
Dicentrine hydrochloride is an adrenergic receptor antagonist known for its anti-inflammatory and anti-cancer properties. It enhances TNF-α-induced apoptosis in A549 lung adenocarcinoma cells by increasing the activities of key apoptotic markers, including caspase-8, -9, -3, and poly(ADP-ribose) polymerase (PARP). Additionally, Dicentrine hydrochloride inhibits TNF-α-induced invasion and migration of A549 cells by downregulating the TAK1, p38, JNK, and Akt signaling pathways, as well as reducing NF-κB and AP-1 transcriptional activities. This compound is valuable for research in cancer biology and therapeutic development. -
MARCKS Inhibitor
BIO-11006 is a specific inhibitor of the MARCKS protein, known for its role in modulating inflammatory responses. This peptide attenuates lipopolysaccharide (LPS)-induced neutrophil influx into lung tissues, suppresses NF-κB activation, and reduces the expression of proinflammatory cytokines such as KC and TNF-α. BIO-11006 has demonstrated efficacy in reversing disease progression in an LPS-induced mouse model of lung injury, making it a valuable tool for research into acute lung injury and acute respiratory distress syndrome (ALI/ARDS). -
NF-κB Inhibitor
Demethyleneberberine chloride is an NF-κB inhibitor that exhibits significant anti-inflammatory properties. This compound has been shown to alleviate colitis in murine models by modulating inflammatory responses through inhibition of the NF-κB pathway and regulation of T helper cell balance. Additionally, Demethyleneberberine chloride acts as an AMPK activator, making it a valuable reagent for research into non-alcoholic fatty liver disease (NAFLD). -
HDAC Inhibitor
CM-444 is a potent inhibitor of histone deacetylases (HDACs) with an IC50 range of 6 nM to 0.6 μM, and demonstrates inhibition of DNA methyltransferases (DNMT) with IC50 values between 1.8 and 2.3 μM. This compound facilitates the differentiation of acute myeloid leukemia cells and exhibits significant anti-leukemic activity, enhancing survival rates in mouse models. CM-444 serves as a valuable tool for research into cancer epigenetics and the development of targeted therapies for leukemia. -
CARM1/HDAC2 inhibitor
CARM1/HDAC2-IN-1 is a dual inhibitor targeting both CARM1 and HDAC2, exhibiting IC50 values of 3.71 nM and 4.07 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. CARM1/HDAC2-IN-1 is suitable for studies investigating the role of these epigenetic regulators in tumor biology and therapeutic strategies. -
PAK1 Inhibitor
AK963/40708899 is a selective inhibitor of PAK1, disrupting the PAK1-NF-κB-cyclinB1 signaling pathway. This compound effectively suppresses the proliferation of human gastric cancer cells and induces G2 phase cell cycle arrest, consequently reducing migration and invasion. Additionally, AK963/40708899 inhibits filopodia formation and enhances cell adhesion, negatively regulating the PAK1-LIMK-cofilin and PAK1-ERK-FAK pathways, thereby diminishing the invasive potential of gastric cancer cells. This reagent is valuable for research into cancer biology and therapeutic interventions targeting PAK1 signaling pathways. -
SIRT1 Modulator
Cannabisin F is a modulator of SIRT1, derived from hempseed lignanamide. It exhibits significant anti-inflammatory and antioxidant properties, making it a valuable candidate for research focused on neurodegenerative diseases. Cannabisin F may influence critical pathways involving SIRT1, NF-κB, and Nrf2, contributing to its potential therapeutic applications. -
Sesquiterpene Compound
β-Curcumene is a sesquiterpene compound known for its potential to activate SIRT1 and inhibit NF-κB pathways. This compound exhibits significant biological activity, making it valuable in research related to metabolic disorders such as type 2 diabetes. Additionally, β-Curcumene's aromatic properties render it useful in the development of flavors, fragrances, and cosmetic applications. -
SIRT1 Activator
SRTCX1002 is a selective activator of the SIRT1 enzyme, functioning primarily through the promotion of p65 deacetylation, which subsequently inhibits NF-κB activity. This compound effectively suppresses inflammatory responses, demonstrated by its ability to inhibit stimuli-induced NF-κB transcriptional activation and reduce LPS-induced TNFα secretion, with IC50 values of 0.71 µM and 7.58 µM, respectively. SRTCX1002 serves as a valuable reagent for research focused on inflammation and related signaling pathways. -
HDAC Inhibitor
HDAC-IN-54 is a potent histone deacetylase (HDAC) inhibitor, exhibiting IC50 values of 25 nM for human HDAC1, 66 nM for HDAC2, 6.5 nM for HDAC3, and 281 nM for HDAC6. This compound effectively induces acetylation of α-tubulin and histone H3, promoting cancer cell apoptosis, particularly in synergy with cisplatin. HDAC-IN-54 is relevant for research applications in head and neck cancer, ovarian cancer, and tongue squamous cell carcinoma. -
Anti-neuroinflammatory Agent
SB26019 is a potent anti-neuroinflammatory agent that primarily targets NF-κB activation. It functions by promoting the formation of monomeric α-tubulin, which in turn inhibits the translocation of the p65 subunit of NF-κB. This mechanism underscores its potential application in neuroscience research, particularly in studies related to neuroinflammation and associated disorders. -
MyD88 Inhibitor
T6167923 is a selective inhibitor of MyD88-dependent signaling pathways, targeting the Toll/IL-1 receptor (TIR) domain of MyD88 to disrupt its homodimeric formation. This compound effectively inhibits NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity, demonstrating notable anti-inflammatory effects with IC50 values of 2.7 μM for IFN-γ, 2.9 μM for IL-1β, 2.66 μM for IL-6, and 2.66 μM for TNF-α. T6167923 serves as a valuable tool in studying the role of MyD88 signaling in inflammatory responses and therapeutic interventions. -
Myd88 Inhibitor
MyD88-IN-1 is a potent inhibitor of MyD88, targeting the interaction between TLR4 and MyD88. By suppressing the NF-κB signaling pathway, MyD88-IN-1 demonstrates significant biological activity relevant to cancer and inflammatory research. This compound serves as a valuable tool for elucidating the role of MyD88 in various disease processes and therapeutic interventions.
